Nasus Pharma appointed Brendan P. O'Grady as Chief Executive Officer, effective July 27, 2026. O'Grady succeeds Dan Teleman as the company advances its lead product candidate toward a pivotal trial in the fourth quarter of 2026.
The candidate, NS002, is an intranasal epinephrine treatment for anaphylaxis. O'Grady will lead the pre-commercial strategy for the product, which targets an estimated $2 billion market.
O'Grady brings over 30 years of pharmaceutical industry experience to the role. He previously served as CEO of Teva USA during a 21-year tenure at Teva Pharmaceuticals and was most recently CEO of Assertio Holdings.
His leadership will also focus on advancing the company's proprietary intranasal technology platform. O'Grady is tasked with further developing the broader clinical product pipeline.